Summary
RCC is a common malignancy with an incidence that has risen over
the last 30 years largely due to incidental findings on imaging. During this
time, the evaluation and management of RCC has evolved due to a greater
understanding of the genetics of the disease, changes in the TNM staging
system, and a trend to less invasive and organ-sparing surgical treatments.
Minimally invasive procedures will continue to be at the forefront of treatment
in the decades to come. With the advent of biologic response modifiers,
additional therapies are now available for patients with metastatic RCC. Nurses
and physicians caring for patients with RCC must be knowledgeable about these
newer treatment modalities, which patients are appropriate candidates for such
therapies, anticipated response rates, and the management of potential adverse
effects. A multidisciplinary approach, which includes nurses and allied
personnel, will continue to be vital in the management of these patients.
